
ãã©ã³ãæ°ãã¬ã¿ãã«ããã®ã³ã³ããã·ã§ããŒãã»ãŠãŒã¹äºäŸã«é¢é£ã
身å äžæã®79æ³ã®ç·æ§ãä»å¹Žæ¥ãã€ãŒã©ã€ãªãªãŒç€Ÿã®æãææãªæ²»éšè¬ãžã®æ©æã¢ã¯ã»ã¹ãç¬å çã«èªããããããã®è¬ã¯ã¬ã¿ãã«ããããŸã FDAã®æ¿èªãåããŠããããäžè¬ã«ã¯å ¥æã§ããªãããã£ãäžäººãæã«å ¥ããããã®äººç©ã®èº«å ã¯ç¢ºèªãããŠããªããããããç¶æ³ããå€ãã®èšè ãå»çé¢ä¿è ã¯åãçµè«ã«éãããæ£è ã¯ã»ãŒééããªãããã«ãã»ãã©ã³ãå倧統é ã§ããã ãã®å ±éã¯ãã©ã€ããµã€ãšã³ã¹å°éã¡ãã£ã¢ã®STATãã¥ãŒã¹ã6æ23æ¥ã«è©³çްã«å ±ãããã®ã ãSTATã«ãããšãåœç«è¡çç ç©¶æïŒNIHïŒã®äžçŽèšåºå»ã2026幎4æãFDAã«å¯ŸããŠå人æ£è æ¡å€§ã¢ã¯ã»ã¹ïŒã³ã³ããã·ã§ããŒãã»ãŠãŒã¹ïŒç³è«ãæåºãã€ãŒã©ã€ãªãªãŒç€Ÿã®3éãã«ã¢ã³äœçšãæã€è¥æºæ²»çè¬ã§ããŸã èšåºè©Šéšäžã®ã¬ã¿ãã«ããããååãæãããªãäžäººã®æ£è ã«æäžããæ¿èªãæ±ãããFDAã¯ãããæ¿èªãã€ãŒã©ã€ãªãªãŒç€Ÿãè¬ãæäŸãããã©ã¡ãã®åœäºè ãæ£è ã®èº«å ã確èªããªãã£ãã ç¶æ³èšŒæ ã¯ååã«æã£ãŠããã æ£è ã¯4ææç¹ã§79æ³ããã©ã³ãæ°ã¯6æ14æ¥ã«80æ³ã®èªçæ¥ãè¿ãããæ£è ã¯çŽ1幎éãã€ãŒã©ã€ãªãªãŒç€Ÿã®æ¿èªæžã¿è¥æºæ²»çè¬ã¶ããããŠã³ãïŒãã«ãŒãããïŒã§æ²»çãåããŠããããäœéæžå°ã¯ç·©ããã ã£ãããã©ã³ãæ°ã¯1æãGLP-1è¬ãæçšããããšã¯ãªãããããããæçšãã¹ãã ããšèšè å£ã«èªã£ãŠãããæ£è ã®æ åœå»ã¯ã幎霢ãšäœµåçŸæ£ãçç±ã«æžéæè¡ãå§ããªãã£ãããã©ã³ãæ°ãéäœéã§ããããšã¯é·å¹Žç¥ãããŠãããå æã®å¹Žæ¬¡å¥åº·èšºæã§ã¯BMIãèšåºçè¥æºã®åºæºå€ã«è¿ãã£ãã STATã¯ããã®äºäŸããä¿å¥çé«å®ã®é¢å¿ãéããããšå ±ããŠãããåã¡ãã£ã¢ã®æ å ±çã¯ãæ£è ãæ¿æ²»çã«åœ±é¿åãæã€èšŒæ ã ãšè§£éãããNIHã®äžçŽèšåºå»ãæåºããã³ã³ããã·ã§ããŒãã»ãŠãŒã¹ç³è«ãHHSã®æäžå±€éšã§æ³šç®ãããã®ã¯ãå¿åã®äžè¬åžæ°ã«ãšã£ãŠéåžžããåŸãªãããšã ã ãã¯ã€ãããŠã¹ã¯åŠå®ãããå ±éå®ã®ã¯ã·ã¥ã»ããµã€æ°ã¯ããã®ç³è«ã¯å€§çµ±é ã®ããã®ãã®ã§ã¯ãªãããšè¿°ã¹ãããããããã®å£°æã¯ç¯å²ãçããåé¡ã解決ãããããªè©³çްãæããã«æ¬ ããŠãããSTATããã©ã³ãæ°ã«ç³è«æžã«èšèŒãããçç¶ïŒé塿§ç¡ç æç¡åŒåžãšèºé«è¡å§çïŒããããã©ãããå°ãããšãããããµã€æ°ã¯å€§çµ±é ã®å¥åº·èšºææžãææããããã®æžé¡ã«ã¯ã©ã¡ãã®çç¶ãèšèŒãããŠããªãã åäŸãããã2020幎ããã©ã³ãæ°ã¯ç·æ¥äœ¿çšèš±å¯ãåããåã«ãã¬ãžã§ããã³ç€Ÿã®COVID-19ã«å¯Ÿããã¢ãã¯ããŒãã«æäœæ²»çè¬ãã³ã³ããã·ã§ããŒãã»ãŠãŒã¹ã§ç±³åœå ã§æåã«æäžãããäžäººãšãªã£ãããã®åŸã圌ã¯ãã®è¬ãç©æ¥µçã«å®£äŒããããã¿ãŒã³ã¯äžè²«ããŠãããæ²»éšè¬ãææã瀺ããšããã©ã³ãæ°ã¯æ©æã«å ¥æããæ¹æ³ãèŠã€ããã®ã§ããã è¬ãã®ãã®ãéèŠã ãã¬ã¿ãã«ããã¯GLP-1äœåè¬ã®æ¬¡äžä»£åã§ããªãŒã³ããã¯ãã¶ããããŠã³ããã匷åã§ãããã€ãŒã©ã€ãªãªãŒç€Ÿã®æ²»éšçµæã§ã¯ãæ£è ã¯80é±éã§å¹³å28ã30ïŒ ã®äœéæžå°ã瀺ããæžéæè¡ã«è¿ã广ã瀺ããããã®è¬ã¯FDAã®æ¿èªãåããŠããªãããã§ã«èŠå¶ãåããŠããªããªã³ã©ã€ã³è²©å£²æ¥è ãéããŠæµéããŠããããã°ã¬ãŒããŒã±ããããå ¥æããè ã¯å»çç£ç£ãªãã§ã®ãªã¹ã¯ã«çŽé¢ããã ã³ã³ããã·ã§ããŒãã»ãŠãŒã¹å¶åºŠïŒæ£åŒã«ã¯æ¡å€§ã¢ã¯ã»ã¹ãšåŒã°ããïŒã¯ãæ·±å»ãªçåœãè ããçŸæ£ãæã€æ£è ã§ä»ã«æ²»çæ³ããªã人ã®ããã«èšèšããããæ«æããæ£è ã屿©çãªãšã€ãºæ£è ã®ããã«äœããããã®ã ããããäœé管çã«é©çšããããšã¯ã䜵åçŸæ£ã䌎ãè€éãªçäŸã§ãã£ãŠããå¶åºŠæ¬æ¥ã®ç®çãéžè±ããŠãããè¥æºã«èŠããäœçŸäžäººãã®ç±³åœäººããå ã«ãäžäººã®æ£è ãæ¿èªåã®å»è¬åãå ¥æããããšã¯ãã·ã¹ãã ãååã«çããŠããªãåããæèµ·ããïŒèª°ãåãé£ã³è¶ããæš©å©ãæã€ã®ãïŒ ã€ãŒã©ã€ãªãªãŒç€Ÿã®CEOããããã»ãªãã¯ã¹æ°ã¯ãã©ã³ãæ¿æš©ãšè¯å¥œãªé¢ä¿ãç¯ããŠãããä»å¹Žåãã«ã¯ããŒã»ã¢ã»ã©ãŽã§ã®å€é£äŒã«åºåžãããå»è¬åäŸ¡æ Œæ¿çãèŠå¶å€æã«åœ±é¿åãè¡äœ¿ã§ãã倧統é ãšè¯å¥œãªé¢ä¿ãç¶æããçç±ã¯å瀟ã«ããããã³ãã®ããæ£è ãžã®ã³ã³ããã·ã§ããŒãã»ãŠãŒã¹æ¿èªã¯ããã²ããã®èšŒæã§ã¯ãªãããç±³åœã§æ²»éšè¬ãžã®ã¢ã¯ã»ã¹ãå®éã«ã©ã®ããã«æ©èœãããã®ãã¿ãŒã³ã«åèŽããŠããã ãã¯ã€ãããŠã¹ã®åŠå®ãå瀟ã®ã³ã¡ã³ãæåŠãFDAã®æ²é»ã¯åé¡ãæªè§£æ±ºã®ãŸãŸã«ããŠãããæ£è ããã©ã³ãæ°ã§ãããšãã蚌æ ãæç€ºããè ã¯ããªããããã§ã¯ãªããšãã蚌æ ãæç€ºããè ãããªããæãããªããšã¯ãäœçŸäžäººãã®äººã ãæã«ã§ããªãè¬ãäžäººãæã«å ¥ããå ¥æå¯èœãªãã¹ãŠã®æããããåãæ¹åãæããŠãããšããããšã ã é å èš³










